Maria Trojanowska, PhD
Professor
Boston University School of Medicine
Dept of Medicine
Rheumatology

PhD, Polish Academy of Sciences
MSc, University of Warsaw




Dr. Trojanowska’s research is aimed at understanding the molecular and cellular mechanisms that regulate ECM synthesis in healthy tissues and in pathological conditions such as fibrosis and tumorigenesis. The majority of her studies focus on the pathogenesis of scleroderma, an autoimmune disease characterized by vascular abnormalities and a prominent fibrosis of the skin. Her laboratory uses molecular and cellular approaches and various experimental models to elucidate the mechanisms responsible for uncontrolled ECM deposition and vessel degeneration in scleroderma. The second area of investigation is related to activation of tumor stroma. These studies examine the molecular mechanisms that mediate controlled regulation of ECM turnover in healthy connective tissue and are responsible for dysregulation of this process during tumorigenesis. Recent studies together with Dr. Lafyatis are examining the role of ER stress in systemic sclerosis.

Director
Boston University School of Medicine
Arthritis & Autoimmune Diseases Research Center


Member
Boston University
BU-BMC Cancer Center


Member
Boston University
Pulmonary Center


Member
Boston University
Evans Center for Interdisciplinary Biomedical Research


Member
Boston University
Genome Science Institute


Graduate Faculty (Primary Mentor of Grad Students)
Boston University School of Medicine, Graduate Medical Sciences




GATA-6 in pulmonary arterial hypertension
03/05/2020 - 01/31/2024 (PI)
NIH/National Heart, Lung, and Blood Institute
5R01HL150638-02

Translational studies for identifying and targeting novel pathways in systemic sclerosis pathogenesis
09/22/2017 - 08/31/2022 (Subcontract PI)
University of Pittsburgh NIH NIAMS
5P50AR060780-09

Regulation of lymphatic system in scleroderma
04/01/2020 - 03/31/2022 (PI)
Scleroderma Foundation


Molecular mechanism of vasculopathy and fibrosis in scleroderma
05/06/2014 - 04/30/2020 (PI)
NIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases
5R01AR042334-24

Preclinical assesment of dimethylfumarate (Tecfidera) as a novel therapeutic for SSC-PAH
04/01/2017 - 09/30/2019 (PI)
Scleroderma Foundation


TGF -beta receptor/Endoglin signaling and the origin of scleroderma fibroblasts
09/01/2015 - 08/31/2017 (PI)
NIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases
2R56AR044883-16

The Functional Biology of Oncostatin M (OSM) and Interleukin (IL)-6/ Soluble IL-6 Receptor in Endothelial Cells
08/24/2015 - 08/23/2016 (PI)
GlaxoSmithKline Research & Development Limited


TGF-Beta Receptor Signaling Scleroderma
10/01/2009 - 05/31/2014 (PI)
NIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases
5R01AR044883-15

The Molecular Mechanisms of Fibrosis
08/10/1994 - 03/31/2013 (PI)
NIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases
5R01AR042334-19



Title


Yr Title Project-Sub Proj Pubs
2021 GATA-6 in pulmonary arterial hypertension 5R01HL150638-02
2021 Project 2: Scleroderma-Associated Pulmonary Arterial Hypertension: The Role of the Oxidant State 5P50AR060780-10-6919 80
2020 GATA-6 in pulmonary arterial hypertension 1R01HL150638-01
2020 GATA-6 in pulmonary arterial hypertension 1R01HL150638-01
2020 Project 2: Scleroderma-Associated Pulmonary Arterial Hypertension: The Role of the Oxidant State 5P50AR060780-09-6919 80
2019 Project 2: Scleroderma-Associated Pulmonary Arterial Hypertension: The Role of the Oxidant State 5P50AR060780-08-6919 80
2018 The molecular mechanism of vasculopathy and fibrosis in scleroderma 5R01AR042334-24 71
2018 Project 2: Scleroderma-Associated Pulmonary Arterial Hypertension: The Role of the Oxidant State 5P50AR060780-07-6919 80
2017 The molecular mechanism of vasculopathy and fibrosis in scleroderma 5R01AR042334-23 71
2017 Project 2: Scleroderma-Associated Pulmonary Arterial Hypertension: The Role of the Oxidant State 2P50AR060780-06A1-6919 80
Showing 10 of 60 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Ferdous A, Singh S, Luo Y, Abedin MJ, Jiang N, Perry CE, Evers BM, Gillette TG, Kyba M, Trojanowska M, Hill JA. Fli1 Promotes Vascular Morphogenesis by Regulating Endothelial Potential of Multipotent Myogenic Progenitors. Circ Res. 2021 Sep 21. PMID: 34544261
     
  2. Lenna S, Tan FK, Trojanowska M. Letter of Retraction. J Immunol. 2021 06 01; 206(11):2763.View Related Profiles. PMID: 34045319; DOI: 10.4049/jimmunol.2100171;
     
  3. Miura S, Watanabe Y, Saigusa R, Yamashita T, Nakamura K, Hirabayashi M, Miyagawa T, Yoshizaki A, Trojanowska M, Sato S, Asano Y. Fli1 deficiency suppresses RALDH1 activity of dermal dendritic cells and related induction of regulatory T cells: a possible role in scleroderma. Arthritis Res Ther. 2021 05 08; 23(1):137. PMID: 33964960; DOI: 10.1186/s13075-021-02520-z;
     
  4. Farina A, Rosato E, York M, Gewurz BE, Trojanowska M, Farina GA. Innate Immune Modulation Induced by EBV Lytic Infection Promotes Endothelial Cell Inflammation and Vascular Injury in Scleroderma. Front Immunol. 2021; 12:651013.View Related Profiles. PMID: 33953718; DOI: 10.3389/fimmu.2021.651013;
     
  5. Nakamura K, Taniguchi T, Hirabayashi M, Yamashita T, Saigusa R, Miura S, Takahashi T, Toyama T, Ichimura Y, Yoshizaki A, Trojanowska M, Fujiu K, Nagai R, Sato S, Asano Y. Altered Properties of Endothelial Cells and Mesenchymal Stem Cells Underlying the Development of Scleroderma-like Vasculopathy in KLF5+/- ;Fli-1+/- Mice. Arthritis Rheumatol. 2020 12; 72(12):2136-2146. PMID: 32627966; DOI: 10.1002/art.41423;
     
  6. Mazzotta C, Marden G, Farina A, Bujor A, Trojanowski MA, Trojanowska M. FLI1 and ERG protein degradation is regulated via Cathepsin B lysosomal pathway in human dermal microvascular endothelial cells. Microcirculation. 2021 01; 28(1):e12660.View Related Profiles. PMID: 32979864; DOI: 10.1111/micc.12660;
     
  7. Marden G, Wan Q, Wilks J, Nevin K, Feeney M, Wisniacki N, Trojanowski M, Bujor A, Stawski L, Trojanowska M. The role of the oncostatin M/OSM receptor ß axis in activating dermal microvascular endothelial cells in systemic sclerosis. Arthritis Res Ther. 2020 07 31; 22(1):179.View Related Profiles. PMID: 32736577; DOI: 10.1186/s13075-020-02266-0;
     
  8. Bujor AM, El Adili F, Parvez A, Marden G, Trojanowska M. Fli1 Downregulation in Scleroderma Myeloid Cells Has Profibrotic and Proinflammatory Effects. Front Immunol. 2020; 11:800.View Related Profiles. PMID: 32508810; DOI: 10.3389/fimmu.2020.00800;
     
  9. Huang M, Cai G, Baugh LM, Liu Z, Smith A, Watson M, Popovich D, Zhang T, Stawski LS, Trojanowska M, Georgakoudi I, Black LD, Pioli PA, Whitfield ML, Garlick J. Systemic Sclerosis Dermal Fibroblasts Induce Cutaneous Fibrosis Through Lysyl Oxidase-like 4: New Evidence From Three-Dimensional Skin-like Tissues. Arthritis Rheumatol. 2020 05; 72(5):791-801.View Related Profiles. PMID: 31705627
     
  10. Stochmal A, Czuwara J, Trojanowska M, Rudnicka L. Antinuclear Antibodies in Systemic Sclerosis: an Update. Clin Rev Allergy Immunol. 2020 Feb; 58(1):40-51. PMID: 30607749
     
Showing 10 of 173 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 173 publications over 35 distinct years, with a maximum of 17 publications in 2017

YearPublications
19841
19873
19881
19891
19903
19911
19925
19931
19941
19953
19962
19973
19982
19992
20004
20014
20027
20035
200410
20056
20066
20076
200811
20093
201012
20116
20129
20139
20144
20156
20166
201717
20183
20206
20214

Contact for Mentoring:

75 E. Newton St Evans Building
Boston MA 02118
Google Map


Trojanowska's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department